艾曲泊帕治疗儿童免疫性血小板减少症:对间充质基质细胞铁代谢的调节作用
本研究首次分析艾曲泊帕(ELT)对儿童免疫性血小板减少症(ITP)患者间充质基质细胞(MSCs)的影响,发现ELT能直接恢复ITP-MSCs的存活与活性,并通过调节铁代谢间接促进其存活与增殖。
要点
- ELT可直接影响ITP-MSCs,恢复其受损的存活与活性。
- ELT通过调节铁代谢间接促进ITP-MSCs的存活与增殖。
- ELT具有铁螯合特性,可减少细胞内铁积累所致细胞损伤。
核心结论
- ELT能直接恢复ITP-MSCs的存活与活性,并通过调节铁代谢间接促进其存活与增殖。
研究设计与样本
- 首次分析ELT对儿童ITP患者间充质基质细胞(MSCs)影响的体外研究。
主要发现
- ITP-MSCs的活性与存活受到严重损害。
- ELT能直接恢复ITP-MSCs的存活与活性。
- ELT通过调节铁代谢间接促进ITP-MSCs的存活与增殖。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is an autoimmune disease caused by platelet destruction mediated by auto-antibody production. It is characterized by a compromised immune system and alteration of the inflammatory response. Mesenchymal stromal cells (MSCs) play an important role in modulating immune and inflammatory processes, exerting immune-suppressing and anti-inflammatory properties. In ITP-MSCs the activity and survival are strongly impaired. Eltrombopag (ELT) is a thrombopoietin receptor agonist approved in chronic ITP for stimulating platelet production. It has immunomodulating properties by stimulating T and B regulatory cell activity and by promoting a macrophage switch from the pro-inflammatory to the anti-inflammatory phenotype. ELT also exhibits iron-chelating properties. Iron is a crucial element involved in several physiologic processes, but its intracellular accumulation determines cell damages. Therefore, for the first time we analysed the effect of ELT on ITP-MSCs demonstrating its ability to restore survival and activity of MSCs directly and to promote their survival and proliferation indirectly, by iron metabolism modulation.
引用
- Di Paola A, Palumbo G, Tortora C, et al. Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells. Br J Haematol. 2021. PMID: 34961933. doi:10.1111/bjh.18012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。